(NASDAQ: IPHA) Innate Pharma Sa's forecast annual revenue growth rate of 6.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Innate Pharma Sa's revenue in 2024 is $67,001,086.On average, 2 Wall Street analysts forecast IPHA's revenue for 2024 to be $4,144,148,556, with the lowest IPHA revenue forecast at $1,971,909,942, and the highest IPHA revenue forecast at $6,316,387,170. On average, 2 Wall Street analysts forecast IPHA's revenue for 2025 to be $3,223,763,010, with the lowest IPHA revenue forecast at $2,222,924,182, and the highest IPHA revenue forecast at $4,224,601,838.
In 2026, IPHA is forecast to generate $7,313,203,334 in revenue, with the lowest revenue forecast at $1,827,898,567 and the highest revenue forecast at $12,798,508,101.